Technical Data
10 Oct 2022

Overview Available MAs

PDF 8 kB

Available Marketing Authorizations 

Content provided by our supplier

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
  • 1000 - 4999
Company types
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer

Other Content from Centrient Pharmaceuticals (7)

  • News Centrient Pharmaceuticals announces completion of acquisition of Astral SteriTech

    Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the completion of the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”).

    With the addition of Astral SteriTech’s Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin sterile injectable finished dosage forms to Centrient’s product portfolio, the company can now further meet the needs of customers and reach more patients with its critical life-saving medicine.

  • Brochure Finished Dosage Forms Portfolio

    Centrient Pharmaceuticals is a business-to-business provider of generics FDFs, not marketing the products ourselves. Therefore, we do not compete with our customers in the end market. All our dossiers are readily available for out-licensing to our partners worldwide. We work primarily with Europe-based FDFs manufacturers. Customers can be confident that the origin, traceability, and quality of our products are impeccable. We offer a dual sourcing strategy and procurement excellence for our third-party-produced APIs.
  • News Our PureActives® partnerships

    With our innovative enzymatic platform, we've been changing the game for sustainable antibiotics and statins production, step by step.
  • Brochure API Product Portflio

    We are a leading business-to-business provider of generic APIs. We help to secure patient safety, by driving Quality to the next level. Our reputation for producing high-quality generic APIs is well-known throughout the industry. Additionally, our business-to-business customers using our enzymatically produced APIs enjoy the freedom to operate, as these technologies are protected by patents.
  • News Centrient Pharmaceuticals to boost statins manufacturing capacity

    Doubling our API capacity to meet the growing demand